Demographic Modulators of Cardiometabolic Risk: A Comprehensive Review of Lipid, Glycemic, and Inflammatory Biomarkers

1. World Health Organization. Noncommunicable diseases. Geneva: WHO; 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
2. Pan American Health Organization. Noncommunicable Diseases. Washington, DC: PAHO; 2025.
3. World Health Organization. Global Health Estimates 2021: Deaths by cause, age, sex, by country and by region, 2000-2021. Geneva: WHO; 2023.
4. Ajoolabady A, Praber D, Bhatt A, et al. Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell Death Dis. 2024;15:817.
5. American Diabetes Association. Diabetes Diagnosis & Tests. Arlington, VA: ADA; 2024.
6. Banach M, Burchardt P, Chlebus K, et al. 2023: the year in cardiovascular disease—the year of new and prospective lipid-lowering therapies. Arch Med Sci. 2023;19(6):1429-1439.
7. Cavagnolli G, Pimentel AL, Freitas PAC, Gross JL, Camargo JL. Effect of ethnicity on HbA1c levels in individuals without diabetes: systematic review and meta-analysis. PLoS ONE. 2017;12(2):e0171315.
8. Davidson MB, Schriger DL. Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. Diabetes Res Clin Pract. 2010;87(3):415-21.
9. Rosengren A, Smyth A, Rangarajan S, et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiology (PURE) Study. Lancet Glob Health. 2019;7(6):e748-e760.
10. Davari M, Maracy MR, Khorasani E. Socioeconomic status, cardiac risk factors, and cardiovascular disease: a novel approach to determine the relative contribution of socioeconomic status to cardiovascular outcomes. ARYA Atheroscler. 2019;15(6):260-267.
11. National Heart, Lung, and Blood Institute. High Blood Cholesterol. Bethesda, MD: NIH; 2024.
12. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472.
13. Pedro-Botet J, Pintó X. LDL cholesterol as a causal agent of atherosclerosis. Clin Investig Arterioscler. 2025;37(2):100051.
14. Maiolino G, Rossitto G, Caielli P, Bisogni V, Rossi GP, Calò LA. The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm. 2013;2013:714653.
15. StatPearls. Atherosclerosis. Treasure Island, FL: StatPearls Publishing; 2023.
16. Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med. 2014;44(2):211-21.
17. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-1405.
18. Ryczkowska K, Adach W, Janikowski K, Banach M, Bielecka-Dabrowa A. Menopause and women's cardiovascular health: is it really an obvious relationship? Arch Med Sci. 2023;19(2):458-466.
19. Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab. 2011;96(4):885-893.
20. Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport: basic mechanisms and their roles in vascular health and disease. Circ Res. 2019;124(10):1505-1518.
21. Madaudo C, Ferrante G, Ferraro G, Ferraro F, Novo G. Dysfunctional high-density lipoprotein cholesterol and coronary artery disease: a narrative review. J Cardiovasc Dev Dis. 2024;11(9):294.
22. Sacher S, Leitinger N. Deciphering structural aspects of reverse cholesterol transport. Biol Rev. 2023;98(5):1831-1853.
23. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000.
24. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8-15.
25. Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Dimou E, Adamopoulos EG. The triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio as a risk marker for metabolic syndrome and cardiovascular disease. Diagnostics. 2023;13(5):929.
26. Chaudhari A, Sharma R, Patel S. Lipid profile abnormalities in metabolic syndrome patients: a comparative cross-sectional study. Healthcare Bull. 2025;7(2):45-53.
27. Prabhu GS, Devang N, Kamath A. Triglycerides and metabolic syndrome: from basic to clinical understanding. Prostaglandins Other Lipid Mediat. 2025;176:106892.
28. Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130(3):1453-1460.
29. Xu D, Hu Y, Liu W, Zhang W, Li J. Triglyceride-rich lipoproteins and cardiovascular diseases. Front Endocrinol. 2024;15:1409653.
30. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345-1352.
31. Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28(6):1039-1049.
32. Liu M, Wadhera RK, Yeh RW, et al. Cardiovascular health among rural and urban US adults—national health interview survey, 2022. JAMA Cardiol. 2025;10(5):433-441.
33. Riha J, Karabarinde A, Ssenyomo G, et al. Urbanicity and lifestyle risk factors for cardiometabolic diseases in rural Uganda: a cross-sectional study. PLoS Med. 2014;11(7):e1001683.
34. Goyal R, Jialal I. Type 2 Diabetes. Treasure Island, FL: StatPearls Publishing; 2023.
35. Endotext. Diagnostic Tests for Diabetes Mellitus. South Dartmouth, MA: MDText.com, Inc.; 2025.
36. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S20-S42.
37. Diabetes Canada Clinical Practice Guidelines Expert Committee. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2018;42(Suppl 1):S10-S15.
38. Pemberton JS, Sherwin-Martin H, Sherwood-Stevens J, Sheridan-Martin E. Ethnic disparities in HbA1c and hypoglycemia among children and young people with type 1 diabetes. BMJ Open Diabetes Res Care. 2025;13(1):e004369.
39. Rao SS, Disraeli P, McGregor T. Impaired glucose tolerance and impaired fasting glucose. Am Fam Physician. 2004;69(8):1961-1968.
40. Cleveland Clinic. Metabolic Syndrome. Cleveland, OH: Cleveland Clinic; 2025.
41. Kawai T, Autieri MV, Bhattacharyya S. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375-C391.
42. Bonora E, Kiechl S, Willeit J, et al. The metabolic syndrome and cardiovascular disease. Ann Med. 2006;38(1):64-80.
43. Amezcua-Castillo E, González-Pacheco H, Sáenz-San Martín A, et al. C-reactive protein: the quintessential marker of systemic inflammation in coronary artery disease. Biomedicines. 2023;11(9):2444.
44. Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851-863.
45. High-sensitivity C-reactive protein in atherosclerotic cardiovascular disease: to measure or not? US Cardiol Rev. 2024;18:e21.
46. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145-156.
47. American College of Cardiology. ACCEL Lite: C-reactive protein and CV risk in the general population. J Am Coll Cardiol. 2025;85(10):e21.
48. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131-2135.
49. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772.
50. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3):347-355.
51. Lakoski SG, Cushman M, Criqui M, et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152(3):593-598.
52. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98(8):731-733.
53. Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. Int J Med Sci. 2016;13(1):25-38.
54. Morgado F, Martins D, Neves D. Laboratory markers of metabolic syndrome. Explor Endocr Metab Dis. 2024;1(3):76-89.
55. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313(19):1973-1974.
56. Chen R, Zhan Y, Pedersen NL, Hägg S. Biomarkers of ageing: current state-of-art, challenges, and opportunities. MedComm. 2023;4(4):e50.
57. Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS. Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci. 2010;17(6):511-531.
58. Pérez-López FR, Chedraui P, Gilbert JJ, Pérez-Roncero G. Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era. Fertil Steril. 2009;92(4):1171-1186.
59. Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54(25):2366-2373.
60. Noah MLN, Adu-Amankwaah J, Owusu Boateng E, et al. Sex–gender disparities in cardiovascular diseases: the effects of estrogen on eNOS, lipid profile, and NFATs during catecholamine stress. Front Cardiovasc Med. 2021;8:639946.
61. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med. 2009;6 Suppl 1:60-75.
62. Das M, Pal S, Ghosh A. Rural urban differences of cardiovascular disease risk factors in adult Asian Indians. Am J Hum Biol. 2008;20(4):440-445.
63. Cross SH, Mehrotra A, Wadhera RK. Rural-urban disparities in cardiovascular mortality in the US, 1999-2019. J Am Coll Cardiol. 2022;79(11):1097-1105.
64. A comparative study of cardiovascular disease risk factors among urban and rural population: a South Indian city. Int J Community Med Public Health. 2017;4(12):4379-4384.
65. Krishnapillai V, Raman S, Pallivalappila AR, Thomas D. Prevalence and risk factors of metabolic syndrome among urban and rural women in Kerala, India. J Midlife Health. 2021;12(3):191-198.
66. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012;70(1):3-21.
67. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic status and cardiovascular outcomes: challenges and interventions. Circulation. 2018;137(20):2166-2178.
68. Stringhini S, Carmeli C, Jokela M, et al. Socioeconomic status and the 25×25 risk factors as determinants of premature mortality: a multicolort study and meta-analysis of 1.7 million men and women. Lancet. 2017;389(10075):1229-1237.
69. Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132(9):873-898.
70. Hamad R, Penko J, Kazi DS, et al. Association of low socioeconomic status with premature coronary heart disease in US adults. JAMA Cardiol. 2020;5(8):899-908.
71. Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol. 2009;6(11):712-722.
72. Braveman P, Gottlieb L. The social determinants of health: it's time to consider the causes of the causes. Public Health Rep. 2014;129 Suppl 2(Suppl 2):19-31.
73. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34.
74. Pedersen BK, Saltin B. Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 2015;25 Suppl 3:1-72.
75. Centers for Disease Control and Prevention. Health effects of cigarettes: cardiovascular disease. Atlanta, GA: CDC; 2024.
76. American Heart Association. Smoking and cardiovascular disease. Dallas, TX: AHA; 2024.
77. Nakamura M, Nagasawa Y, Yamamoto A, et al. Relationships between smoking status, cardiovascular risk factors, and lipid profile. Circ J. 2020;84(12):2160-2167.
78. He BM, Zhao SP, Peng ZY. Effects of cigarette smoking on HDL quantity and function: implications for atherosclerosis. J Cell Biochem. 2013;114(11):2431-2436.
79. Zhang Y, Ren J. Role of oxidative stress in smoke-related cardiovascular diseases. Redox Biol. 2020;36:101646.
80. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33(5):585-592.
81. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141(11):846-850.
82. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-S73.
83. Goldstein BA, Navar AM, Carter RE. Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. Eur Heart J. 2017;38(23):1805-1814.
84. Trpkovic A, Resanovic I, Stanimirovic J, et al. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci. 2015;52(2):70-85.
85. Babakr AT, Almutairi NM, Alghamdi SA, Alharbi AO. Oxidized low-density lipoproteins and their contribution to atherosclerosis. Explor Cardiol. 2025;3(1):101246.
86. Itabe H, Obama T, Kato R. The dynamics of oxidized LDL during atherogenesis. J Lipids. 2011;2011:418313.
87. Hong CG, Florida E, Li H, Parel PM, Mehta NN, Dey AK. Oxidized low-density lipoprotein associates with cardiovascular disease in populations with chronic inflammation: a systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1069311.
88. Kim-Mitsuyama S, Soejima H, Yasuda O, Node K, Ogawa H. Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial. Sci Rep. 2019;9:16589.
89. Lei X, Qiu S, Yang G, Wu Q. Adiponectin and metabolic cardiovascular diseases: therapeutic perspectives. Front Cardiovasc Med. 2022;9:1054428.
90. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79-83.
91. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007;74(1):11-18.
92. Okamoto Y. Adiponectin provides cardiovascular protection in metabolic syndrome. Cardiol Res Pract. 2011;2011:313179.
93. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597-605.
94. Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther. 2016;30(1):87-100.
95. Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374-392.